Adjuvant Therapies for Esophageal Cancer.

ABSTRACT

Esophageal cancer is the sixth most common cause of cancer mortality worldwide and is considered a major worldwide health challenge. Most patients diagnosed with esophageal cancer require extensive workup and management strategies. Multiple clinical trials have been conducted to evaluate the role of chemotherapy, chemoradiotherapy, and recently immunotherapy before or after surgery in the setting of localized esophageal cancer. Trimodality approaches, including preoperative chemoradiation followed by surgery or perioperative chemotherapy, have been widely accepted for treating localized esophageal cancer. However, the addition of immunotherapy to the current trimodality approach produced an advantage in disease-free survival. Our review will focus on the existing data on adjuvant therapies for locally advanced esophageal and gastroesophageal adenocarcinomas and squamous cell carcinomas.